Kinase is a class of enzyme that helps to transfer phosphate groups to the targeted substrate from molecules with high energy such as adenosine triphosphate (ADP). Disrupted or inappropriate kinase activity has been associated with several chronic diseases such as diabetes, neurological disorders, cancer, and cardiovascular disorders.
The rising prevalence of chronic diseases such as cancer and diabetes is one of the primary factors driving the global kinase-targeted therapeutics market. The World Diabetes Foundation (WDF) estimates the number of people suffering from diabetes to reach 438 million by 2030. Similarly, the World Cancer Research Fund International projects the count of people suffering from cancer across the world to reach 21 million by the same year. Kinases vary on the basis of molecules on which they act. Some of them are lipid kinase, protein kinase, and carbohydrate kinase.
The key segments analyzed in the report based on geography are North America, Asia Pacific, Europe, and Rest of the World. North America will account for a substantial share in the market throughout the review period owing to the presence of a large base of geriatric population. The domicile of large manufacturers of kinase-targeted therapeutic drugs is providing an edge to the region over other regions. In addition, the continuous research and development activities in the field are supporting the growth of the market in the region.
Asia Pacific is expected to exhibit significant growth during the same period. The growth of the region can be attributed to the expanding base of patients suffering from chronic diseases. The improving healthcare infrastructure along with the rising expenditure of the populace on healthcare is propelling the growth of the region.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11468
A large number of pharmaceutical giants are investing in the area of kinase modulation, and are among the leading players in the market. Several companies operating in the global kinase-targeted therapeutics market are keen on designing and launching improved agents that target diverse combinations of kinases. They are focusing towards business development and pipeline enrichment through mergers and acquisitions. Some of the prominent manufacturers of kinase-targeted therapeutic drugs are Eli Lilly and Company, Abbott Laboratories, Avila Therapeutics Inc., Array BioPharma Inc., and Bristol-Myers Squibb Co.